|
C12ORF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.65089999951229E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.00720000001586E-06 |
| Normal-vs-Stage2 |
1.077780E-02 |
| Normal-vs-Stage3 |
2.58940000552599E-08 |
| Normal-vs-Stage4 |
1.71169967089213E-10 |
| Stage1-vs-Stage2 |
6.063000E-01 |
| Stage1-vs-Stage3 |
3.746200E-02 |
| Stage1-vs-Stage4 |
6.603300E-04 |
| Stage2-vs-Stage3 |
7.043700E-02 |
| Stage2-vs-Stage4 |
2.758400E-03 |
| Stage3-vs-Stage4 |
9.454300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.29680005517474E-09 |
| Normal-vs-AfricanAmerican |
3.041600E-03 |
| Normal-vs-Asian |
5.991400E-04 |
| Caucasian-vs-AfricanAmerican |
5.391200E-01 |
| Caucasian-vs-Asian |
2.862400E-01 |
| AfricanAmerican-vs-Asian |
8.761400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.73600000000718E-07 |
| Normal-vs-Female |
6.52079999996502E-08 |
| Male-vs-Female |
6.703400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.801400E-04 |
| Normal-vs-Age(41-60Yrs) |
6.39780006750357E-10 |
| Normal-vs-Age(61-80Yrs) |
8.30730000012103E-07 |
| Normal-vs-Age(81-100Yrs) |
1.829590E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.776950E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.850500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.530000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.191400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.871400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.223200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.296440E-01 |
| Classical-VS-Follicular |
1.089420E-01 |
| Classical-VS-Other |
8.517900E-02 |
| Classical-VS-Normal |
1.31189999996728E-06 |
| Tall-VS-Follicular |
1.260210E-02 |
| Tall-VS-Other |
3.261400E-01 |
| Tall-VS-Normal |
5.66540000024318E-07 |
| Follicular-VS-Other |
7.086000E-02 |
| Follicular-VS-Normal |
1.072420E-02 |
| Other-VS-Normal |
9.92699999999846E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.64080000003764E-06 |
| Normal-vs-N1 |
1.99489999963554E-07 |
| N0-vs-N1 |
3.046000E-02 |
|
|
